» Articles » PMID: 8476561

The IL-2 Receptor Complex: Its Structure, Function, and Target Genes

Overview
Date 1993 Jan 1
PMID 8476561
Citations 141
Authors
Affiliations
Soon will be listed here.
Abstract

Proliferation of T lymphocytes is triggered by the interaction of IL-2 with its specific receptor following T lymphocyte activation. The receptor for IL-2 consists of at least three distinct subunits, the alpha chain (IL-2R alpha), the beta chain (IL-2R beta), and the gamma chain (IL-2R gamma). Although the role of IL-2R gamma in IL-2 signalling remains unclear, IL-2R beta is the subunit critical for receptor-mediated signalling. Because IL-2R beta lacks any apparent catalytic motifs, IL-2R beta may be physically or functionally coupled to other signalling molecules. Structure-function studies of IL-2R beta have revealed that at least two distinct cytoplasmic regions of IL-2R beta are involved in IL-2-induced cellular signalling. The "serine-rich" region of IL-2R beta was identified as a region critical for IL-2-induced mitotic signalling from experiments in which IL-2R beta mutant cDNAs lacking a particular cytoplasmic region or regions were expressed in an IL-3-dependent mouse pro-B cell line (BAF-B03). Meanwhile, another cytoplasmic region of IL-2R beta, the "acidic" region, is responsible for its physical association with an src-family protein tyrosine kinase (PTK), p56lck and is critical for activating the p56lck PTK following IL-2 stimulation. It is now evident that IL-2R beta is linked to at least two intracellular signalling pathways that mediate nuclear proto-oncogene induction. One pathway is linked to tyrosine phosphorylation events, mediated by a src-family protein tyrosine kinase (PTK), and that pathway leads to the induction of the c-fos, c-jun, and other genes of this family. Another pathway leads to c-myc gene induction by an as yet unknown mechanism. We discuss the complex signalling machinery that links the cell surface receptor to the nuclear events.

Citing Articles

Humanized anti-CD25 monoclonal antibody replaces methotrexate as acute graft-versus-host disease prophylaxis in haploidentical allogeneic haematopoietic stem cell transplantation.

Zhang A, Huang Z, Zhang R, Wei R, Jiang S, Chen H Br J Haematol. 2024; 206(2):615-627.

PMID: 39710371 PMC: 11829143. DOI: 10.1111/bjh.19958.


Generation of an Inhibitory NK Cell Subset by TGF-β1/IL-15 Polarization.

Chung D, Garcia-Batres C, Millar D, Wong S, Elford A, Mathews J J Immunol. 2024; 212(12):1904-1912.

PMID: 38668728 PMC: 11149900. DOI: 10.4049/jimmunol.2300834.


Chimeric antigen-receptor (CAR) engineered natural killer cells in a chronic myeloid leukemia (CML) blast crisis model.

Imeri J, Marcoux P, Huyghe M, Desterke C, Fantacini D, Griscelli F Front Immunol. 2024; 14:1309010.

PMID: 38259442 PMC: 10801069. DOI: 10.3389/fimmu.2023.1309010.


Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies.

Muhammad S, Fan T, Hai Y, Gao Y, He J Mol Cancer. 2023; 22(1):121.

PMID: 37516849 PMC: 10385932. DOI: 10.1186/s12943-023-01826-7.


Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review.

Rinaldi I, Winston K J Blood Med. 2023; 14:261-277.

PMID: 37051025 PMC: 10084831. DOI: 10.2147/JBM.S382090.